Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas

Haematologica

Volumn 92, Issue 5, 2007, Pages 686-689

  Pulini, Stefano ^a   Rupoli, Serena ^a   Goteri, Gaia ^a   Pimpinelli, Nicola ^b   Alterini, Renato ^b   Tassetti, Angela ^a   Scortechini, Anna Rita ^a   Offidani, Massimo ^a   Mulattieri, Simonetta ^a   Stronati, Andrea ^a   Brandozzi, Giuliano ^a   Giacchetti, Alfredo ^c   Mozzicafreddo, Giorgio ^c   Ricotti, Giuseppe ^c   Filosa, Giorgio ^d   Bettacchi, Alberta ^d   Simonacci, Marco ^d   Novelli, Nicolino ^e   Leoni, Pietro ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c INRCA   (Italy)

^d Division of Dermatology   (Italy)

^e Dermatology   (Italy)

Author keywords

Mycosis fungoides; Pegylated liposomal doxorubicin; Primary cutaneous T cell lymphomas; S zary syndrome

Indexed keywords

DOXORUBICIN; PYRIDOXINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; LIPOSOME; MACROGOL DERIVATIVE;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR GROWTH; ADULT; AGED; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MYCOSIS FUNGOIDES; REMISSION; SALVAGE THERAPY; SEZARY SYNDROME; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LIPOSOMES; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SALVAGE THERAPY; SEZARY SYNDROME; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34447340691     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10879     Document Type: Article

References (19)

1. Visani G, Guiducci B, D'Adamo F, Mele A, Nicolini G, Leopardi G, et al. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 477-9.
2. Hussein MA, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006;81:889-95.
3. Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, et al. Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for newly diagnosed multiple myeloma patients over 65 years. Blood 2006;108:2159-64.
4. Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006;42:1014-30.
5. Tsatalas C, Martinis G, Margaritis D, Spanoudakis E, Kotsianidis I, Karpouzis, et al. Long-term remission of recalcitrant tumor-stage mycosis fungoides following chemotherapy with pegylated liposomal doxorubicin. J Eur Acad Dermatol Venereol 2003;17:80-2.
6. Di Lorenzo G, Di Trolio R, Delfino M, De Placido S. Pegylated liposomal doxorubicin in stage IV B mycosis fungoides. Br J Dermatol 2005;153:183-5.
7. Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003;98:993-1001.
8. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85.
9. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-53.
10. Common toxicity criteria (CTC) and common terminology criteria for adverse events (CTCAE). Available from URL: http://ctep.cancer.gov/reporting/ ctc.html
11. Zachariae H, Thestrup-Pedersen K. Combination chemotherapy with bleomycin, cyclophosphamide, prednisone and etretinate (BCPE) in advanced mycosis fungoides: a six-year experience. Acta Derm Venereol 1987;67:433-7.
12. Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784-90.
13. Fierro MT, Doveil GC, Quaglino P, Savoia P, Verrone A, Bernengo MG. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma. Dermatology 1997; 194: 268-72.
14. Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003;101:4267-72.
15. Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999;86:1368-76.
16. Tirelli U, Carbone A, Zagonel V, Volpe R, Veronesi A, Galligioni E, et al. Staging and treatment with cyclophosphamide, vincristine and prednisone (CVP) in advanced cutaneous T-cell lymphomas. Hematol Oncol 1986;4:83-90.
17. Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 1998;31:583-8.
18. Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, et al. Gemcitabine as frondine treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005;104:2437-41.
19. van Doom R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F, de Rie M, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504-10.